Physician profile
Robin Hayes
NPI 1164043899
$4,540.45
in general payments reported to CMS, 2019-2025
30 companies · $919 in 2025
The $919 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,281 · 2022: $1,510 · 2023: $689 · 2024: $140 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.27 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $532.30 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $417.07 | 2021-2025 | Ingrezza |
| Ucb, INC. | $235.02 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $226.94 | 2023-2025 | Nuplazid, Daybue |
| Sk Life Science, INC. | $221.60 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $197.87 | 2022 | |
| Biogen, INC. | $186.79 | 2021-2022 | |
| Eisai INC. | $183.77 | 2021-2025 | |
| Amgen INC. | $164.95 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $154.17 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.15 | 2021 | |
| Genzyme Corporation | $125.73 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $117.47 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $91.21 | 2023-2025 | Rexulti, Nuedexta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $83.75 | 2025 | Symbravo |
| Emd Serono, INC. | $72.84 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $69.77 | 2025 | Crexont |
| Lilly USA, LLC | $66.20 | 2021-2022 | |
| Kyowa Kirin, INC. | $58.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.11 | 2021-2022 | |
| Lundbeck LLC | $44.32 | 2021-2025 | Vyepti |
| Pfizer INC. | $38.27 | 2025 | |
| Sun Pharmaceutical Industries INC. | $33.81 | 2021 | |
| Merz Pharmaceuticals, LLC | $27.31 | 2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $26.69 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.26 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.28 | 2022 | |
| Genentech USA, INC. | $17.95 | 2021 | |
| Avion Pharmaceuticals | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.